[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 141,460,192
  • Shares Outstanding, K 5,699,444
  • Annual Sales, $ 62,579 M
  • Annual Income, $ 7,771 M
  • EBIT $ 19,384 M
  • EBITDA $ 25,976 M
  • 60-Month Beta 0.35
  • Price/Sales 2.21
  • Price/Cash Flow 5.52
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 23.95% (-0.45%)
  • Historical Volatility 23.22%
  • IV Percentile 47%
  • IV Rank 35.87%
  • IV High 34.15% on 10/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 8) 0.70 (2.77%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 130,270
  • Volume Avg (30-Day) 116,363
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 2,515,425
  • Open Int (30-Day) 2,396,793
  • Expected Range 24.44 to 25.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.68
  • Number of Estimates 5
  • High Estimate $0.69
  • Low Estimate $0.66
  • Prior Year $0.78
  • Growth Rate Est. (year over year) -12.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.62 +6.44%
on 07/06/26
26.28 -4.34%
on 06/17/26
-0.90 (-3.46%)
since 06/16/26
3-Month
23.62 +6.44%
on 07/06/26
27.84 -9.71%
on 04/20/26
-2.08 (-7.64%)
since 04/16/26
52-Week
23.11 +8.78%
on 08/01/25
28.75 -12.54%
on 04/02/26
+0.53 (+2.15%)
since 07/16/25

Most Recent Stories

More News
Here's What to Expect From Pfizer's Next Earnings Report

Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its profit.

XLV : 161.80 (+2.22%)
$SPX : 7,533.77 (-0.51%)
PFE : 25.14 (+1.29%)
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

AZN : 169.29 (+0.55%)
ALNY : 283.15 (+1.44%)
IONS : 54.65 (-0.15%)
BBIO : 80.30 (-2.86%)
PFE : 25.14 (+1.29%)
2 Value Stocks Worth Your Attention and 1 Facing Headwinds

2 Value Stocks Worth Your Attention and 1 Facing Headwinds

TSN : 57.83 (+0.63%)
PIPR : 77.66 (-0.12%)
PFE : 25.14 (+1.29%)
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

First and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care Broadened...

PFE : 25.14 (+1.29%)
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off

1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off

UFPT : 256.74 (+4.40%)
PFE : 25.14 (+1.29%)
BIIB : 208.92 (+5.92%)
Trump’s Newly Disclosed Moderna Trades Preceded FDA Advisory Panel’s Unanimous Backing of mRNA Flu Vaccine

President Donald Trump’s stock transaction filings reveal multiple purchases of Moderna ($MRNA) during March 2026, followed by a partial sale on May 18. Since those trades, the FDA's Vaccines and Related...

MRNA : 63.15 (-7.51%)
PFE : 25.14 (+1.29%)
GSK : 52.77 (+2.57%)
Haleon Just Struck a Five-Year Deal With Microsoft. Here Is What It Means for Haleon Stock.

Haleon has struck a five-year partnership with Microsoft as it looks to expand its AI transformation using Microsoft's Copilot.

TGT : 140.21 (+1.39%)
MSFT : 401.10 (+1.38%)
$SRCS : 950.54 (+2.90%)
COST : 945.57 (+3.17%)
NVS : 152.73 (+1.28%)
HLN : 10.11 (+3.69%)
GSK : 52.77 (+2.57%)
PFE : 25.14 (+1.29%)
WMT : 114.95 (+2.15%)
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down

2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down

LKQ : 26.01 (+4.37%)
DXCM : 77.98 (+7.22%)
PFE : 25.14 (+1.29%)
2 Large-Cap Stocks to Target This Week and 1 We Find Risky

2 Large-Cap Stocks to Target This Week and 1 We Find Risky

CVNA : 70.66 (+0.10%)
PFE : 25.14 (+1.29%)
MLM : 576.93 (+1.34%)
Pfizer Declares Third-Quarter 2026 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share

PFE : 25.14 (+1.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 25.89
2nd Resistance Point 25.63
1st Resistance Point 25.38
Last Price 25.14
1st Support Level 24.87
2nd Support Level 24.61
3rd Support Level 24.36

See More

52-Week High 28.75
Fibonacci 61.8% 26.59
Fibonacci 50% 25.93
Fibonacci 38.2% 25.26
Last Price 25.14
52-Week Low 23.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.